Published in Immunology on September 01, 1975
Association of sepsis with an immunosuppressive polypeptide in the serum of burn patients. Ann Surg (1978) 1.15
Normal immunosuppressive protein: inhibitory effect on immune response against tumour cells. Immunology (1978) 0.98
The inhibitory effect of normal immunosuppressive protein on lymphocytes mediating natural killing activity. Immunology (1981) 0.79
Normal immunosuppressive protein. Isolation of a glycoprotein active fraction. Immunology (1980) 0.79
Inhibition by human serum of lymphocyte proliferation stimulated by purified protein derivative of tuberculin and bacillus Calmette-Guérin. Infect Immun (1979) 0.75
Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med (1972) 24.43
Cytotoxic effects of lymphoid cells in vitro. Adv Immunol (1969) 8.18
A receptor for antibody on B lymphocytes. I. Method of detection and functional significance. J Exp Med (1972) 7.47
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
The human rosette-forming cell as a marker of a population of thymus-derived cells. J Clin Invest (1972) 4.80
Identification of three different human lymphocyte populations by surface markers. Transplant Rev (1973) 3.41
Transformation of human lymphocytes: inhibition by homologous alpha globulin. Science (1968) 2.55
Effect of large doses of an alpha2-glycoprotein fraction on the survival of rat skin homografts. Transplantation (1963) 1.91
Successful skin bomografts in mature non-littermate rats treated with fractions containing alpha-globulins. Proc Soc Exp Biol Med (1959) 1.82
Bone marrow origin of complement-receptor lymphocytes. Eur J Immunol (1971) 1.80
The effect of immunoregulatory globulin (IRA) upon lymphocytes in vitro. J Immunol (1972) 1.79
The effector cell in antibody-induced cell mediated immunity. Transplant Rev (1973) 1.56
Thymus-dependent and thymus-independent effector functions of mouse lymphoid cells. Comparison of cytotoxicity and primary antibody formation in vitro. Cell Immunol (1973) 1.55
Competitive blockade of lymphocyte stimulation by a serum immuno-regulatory alpha globulin (IRA). Transplant Proc (1969) 1.47
Antibody-dependent lymphocyte-mediated cytotoxicity in man: no requirement for lymphocytes with membrane-bound immunoglobulin. Scand J Immunol (1973) 1.46
Regulation of T lymphocyte function by immunoregulatory alphaglobulin (IRA). J Immunol (1974) 1.29
Prolongation of allograft survival by an alpha globulin isolated from normal blood. Transplantation (1967) 1.24
Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res (1974) 1.01
The effect of immunoregulatory alpha globulin (IRA) on antigen-mediated macrophage immobilization in vitro. J Immunol (1971) 0.96
Immunoregulatory d-globulin: failure to inhibit antibody response when administered after antigen exposure. J Immunol (1973) 0.91
In vitro inhibition of plaque and rosette formation by globulin. J Immunol (1972) 0.87
A nonspecific immunosuppressive material derived from normal bovine serum. Proc Soc Exp Biol Med (1973) 0.85
Inhibitory effect of alpha-globulin on the second set allograft reaction. Proc Soc Exp Biol Med (1972) 0.79
Synergistic effect of -globulin and other immunosuppressive agents on rat skin allograft survival. Transplantation (1972) 0.78
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13
A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst (1984) 2.08
Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes. J Exp Med (1989) 1.60
Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol (1981) 1.58
Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst (1980) 1.49
Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst (1995) 1.47
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans (1997) 1.45
Parent comprehension of polio vaccine information pamphlets. Pediatrics (1996) 1.44
An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis (1988) 1.43
Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine. Anesth Analg (1990) 1.40
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40
Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys (2000) 1.32
Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of natural killer cell-mediated cytotoxicity. Int J Cancer (1980) 1.31
SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet (2009) 1.28
Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol (1984) 1.25
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol (2000) 1.23
Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev (1982) 1.15
Mechanisms of depressed reactivity to dinitrochlorobenzene and ultraviolet-induced tumors during ultraviolet carcinogenesis in BALB/c mice. Cell Immunol (1978) 1.09
Role of natural killer cells in host defense against cancer metastasis. Symp Fundam Cancer Res (1983) 1.08
HLA-DRw4 in pemphigus vulgaris patients in Israel. Tissue Antigens (1980) 1.08
Expression of metastatic potential of allogenic and xenogeneic neoplasms in young nude mice. Cancer Res (1981) 1.06
Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. J Immunol (1983) 1.06
Sexual transmission of human papillomaviruses in heterosexual and male homosexual couples, studied by DNA hybridisation. Genitourin Med (1988) 1.05
"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology (N Y) (1992) 1.04
Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma. J Immunol (1986) 1.04
Effects of prostaglandins and cAMP levels on monocyte IL-1 production. Agents Actions (1989) 1.03
Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res (2007) 1.03
Macrophage activation in rat models of inflammation and arthritis. Systemic activation precedes arthritis induction and progression. Arthritis Rheum (1986) 1.02
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol (2007) 1.02
The role of natural killer cells in the control of tumor growth and metastasis. Biochim Biophys Acta (1985) 1.02
In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother (1997) 1.01
CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibitory cells. Proc Natl Acad Sci U S A (1988) 1.00
SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol (1987) 0.99
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus (2006) 0.99
Normal immunosuppressive protein: inhibitory effect on immune response against tumour cells. Immunology (1978) 0.98
The new Ghent criteria for Marfan syndrome: what do they change? Clin Genet (2011) 0.98
Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol (2013) 0.97
Structural requirements for in vivo and in vitro immunogenicity in hapten-specific delayed hypersensitivity. Cell Immunol (1973) 0.96
Mixed lymphocyte reactivity nonresponsiveness in couples with multiple spontaneous abortions. Fertil Steril (1983) 0.96
Antibodies to species homologous tissue antigens in the rat. II. Circulating antibodies during the development of autoimmune renal disease. Clin Exp Immunol (1967) 0.96
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol (1999) 0.95
Macrophage activation in rat models of inflammation and arthritis: determination of markers of stages of activation. Cell Immunol (1986) 0.95
Normal immunosuppressive protein inhibition of human and murine lymphoblastoid cell line proliferation. Eur J Immunol (1979) 0.95
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin Immunol (2001) 0.94
Effect of anti-epidermis antibodies on autografts and allografts in rats. Nature (1968) 0.94
Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine (1992) 0.94
Normal immunosuppressive protein purification and quantitative estimation experiments. J Immunol Methods (1979) 0.93
A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation. J Immunol (1998) 0.93
Cooperative effects in antibody formation produced by hapten-specific delayed sensitivity. J Immunol (1973) 0.92
Antibodies to species homologous tissue antigens in the rat. I. Naturally occurring circulating antibodies. Clin Exp Immunol (1967) 0.91
Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis. Arthritis Rheum (1988) 0.91
Systematic molecular and cytogenetic screening of 100 patients with marfanoid syndromes and intellectual disability. Clin Genet (2013) 0.90
Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci U S A (1992) 0.90
Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002. Int J Immunopharmacol (1988) 0.89
Evaluation of the Phadebact ETEC-LT test for the heat-labile enterotoxin of Escherichia coli. Zentralbl Bakteriol (1989) 0.89
Effect of Normal Immunosuppressive Protein (NIP) on tumor growth in mice. Eur J Cancer (1975) 0.88
Disputed parentage due to exchanged babies solved by HLA. Vox Sang (1980) 0.88
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol (2005) 0.88
In vitro inhibition of plaque and rosette formation by globulin. J Immunol (1972) 0.87
Role of normal immunosuppressive protein (NIP) in immunologic surveillance. Transplant Proc (1977) 0.87
Inhibition of experimental tumor metastasis by selective activation of natural killer cells. Cancer Res (1982) 0.87
Comparative analysis of HLA polymorphism at the serologic and molecular level in Moroccan and Ashkenazi Jews. Tissue Antigens (1995) 0.87
Labor-associated changes in Fas ligand expression and function in human placenta. Pediatr Res (2000) 0.86
Effect of antiarthritic drugs on the enhanced interleukin-1 (IL-1) production by macrophages from adjuvant-induced arthritic (AA) rats. Agents Actions (1987) 0.86
Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis. Int J Cancer (1982) 0.86
Differential inhibition of histamine release from mast cells by protein kinase C inhibitors: staurosporine and K-252a. Biochem Pharmacol (1990) 0.86
Response of human lymphocytes to PHA and Con A, dependent on and regulated by THF, a thymic hormone. J Immunol (1976) 0.86
Polybrominated diphenyl ethers enhance the production of proinflammatory cytokines by the placenta. Placenta (2012) 0.86
A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol (1997) 0.86
Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol (1988) 0.86
The pharmacology of arachidonic acid-induced rat paw edema. Agents Actions (1987) 0.86
Novel diversity in IL-4-mediated responses in resting human naive B cells versus germinal center/memory B cells. J Immunol (2000) 0.85
Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther (2001) 0.85
In vivo isolation of a metastatic tumor cell variant involving selective and nonadaptive processes. J Natl Cancer Inst (1981) 0.85
Thrombocyte specific antigens. Detection of organ specific antigens by heterospecific anti-thrombocyte serum. Immunology (1969) 0.85
Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice. Antimicrob Agents Chemother (1997) 0.85
Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. Circ Shock (1989) 0.85
Fetal cardiac output in the isoimmunized pregnancy: a pulsed Doppler-echocardiographic study of patients undergoing intravascular intrauterine transfusion. Am J Obstet Gynecol (1989) 0.83
Nonpathogenicity of species-homologous anti-kidney antibodies in the rat. Br J Exp Pathol (1968) 0.83
Effect of anti-epidermins antibodies on autografts in rats and rabbits. Clin Exp Immunol (1969) 0.83
Shortened survival of rat allografts after the rejection of xenografts. Isr J Med Sci (1968) 0.83
Detection of human papillomavirus DNA in the urogenital tracts of men with anogenital warts. Sex Transm Dis (1993) 0.83
Inhibition of plaque formation, rosette formation and phagocytosis by alpha globulin. Immunology (1972) 0.83
Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend (2007) 0.82
Quantitative Western blot assay for measurement of the murine acute phase reactant, serum amyloid P component. J Immunol Methods (1986) 0.82
Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol (2005) 0.82
Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. J Rheumatol (1985) 0.81
Patterns of naturally occurring circulating antibodies to rat tissue antigens in the rat. Pathol Microbiol (Basel) (1968) 0.81
Activation of the IL-1 gene in UV-irradiated mouse skin: association with inflammatory sequelae and pharmacologic intervention. J Invest Dermatol (1991) 0.81
Adjuvant-induced nonspecific supressor cells: in vitro and in vivo studies. Cell Immunol (1980) 0.80
Autoimmune renal disease. Development of renal lesions and circulating antibodies in rats immunized with homologous kidney fractions. Immunology (1967) 0.80
Prolonged survival of skin allografts in rats treated with heterologous anti-skin serum. Clin Exp Immunol (1970) 0.80